Adherence to Single Daily Dose of Aspirin in a Chemoprevention Trial: An Evaluation of Self-report and Microelectronic Monitoring

Archives of Family Medicine

Volumn 5, Issue 5, 1996, Pages 297-300

  Burney, Kimberly D ^a   Krishnan, Koyamangalath ^a   Ruffin, Mack T ^a   Zhang, Daowen ^a   Brenner, Dean E ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 300 Simpson Memorial Bldg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG PACKAGING; ELECTRONICS; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL;

ADULT; ASPIRIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG PACKAGING; ELECTRONICS; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE;

EID: 0030136577     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.5.5.297     Document Type: Article

References (24)

1. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther. 1989;46:163-168.
2. Zelen M. Are primary cancer trials feasible? J Natl Cancer Inst. 1988;80:1442-1444.
3. Arnold AM, Browman GP, Johnstone B, Skingley P, Booker L, Levine MN. Chemoprevention for lung cancer: evidence for a high degree of compliance. Cancer Detect Prev. 1990;5:521-525.
4. Berenson M, Goshen S, Miller H, Decosse J. Subject-reported compliance in a chemoprevention trial for familial adenomatous polyposis. J Behav Med. 1989; 12:233-247.
5. Urquhart J. Noncompliance: the ultimate absorption barrier. In: Prescott LF, Nimmo WS, eds. Novel Drug Delivery and Its Therapeutic Application. New York, NY: John Wiley & Sons Inc; 1989:127-137.
6. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Oulette V. How often is medication taken as prescribed? a novel assessment technique. JAMA. 1989;261: 3273-3277.
7. Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR. Patient noncompliance with self-administered chemotherapy. Cancer. 1990;65:17-22.
8. Rudd P, Byyny RL, Zactory V, et al. The natural history of medication compliance in a drug trial of pill counts. Clin Pharm Ther. 1989;46:170-176.
9. Waterhouse DM, Calzone KA, Mele C, Brenner, D. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;2:1189-1197.
10. Love RR. Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst. 1990;82:18-21.
11. Fischer B, Constantino J, Redmond C. A randomized trial evaluation of tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-positive tumors. N Engl J Med. 1989;320:479-484.
12. Cramer JA, Mattson RH. Monitoring compliance with antiepileptic drug therapy. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York, NY: Raven Press; 1991:123-137.
13. Maenpaa H, Javela K, Pikkarainen J, Malkonen M, Heinonen OP, Manninen V. Minimal doses of digoxin: a new marker for compliance to medication. Eur Heart J. 1987;8(suppl 1):31-37.
14. Maenpaa H, Manninen V, Heinonen OP. Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J. 1987;8(suppl 1):39-43.
15. Black DM, Brand RJ, Greenlick M, Hughes G, Smith J. Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. J Gerontol. 1987;42:552-557.
16. Sackett DL. Hypertension in the real world: public reaction, physician response, and patient compliance. In: Genest J, Koiw E, Kuchel O, eds. Hypertension: Physiopathology and Treatment. New York, NY: McGraw-Hill International Inc; 1977:1142-1149.
17. Greenberg ER, Baron JA, Freeman D Jr, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users: the polyp prevention study group. J Natl Cancer Inst. 1983;11:912-916.
18. Paganini-Hill A, Chao A, Ross R, Henderson B. Aspirin use and chronic disease: a cohort study of elderly. BMJ. 1989;6710:127-150.
19. Paganini-Hill A, Hsu G, Ross RK, Henderson BE. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1992;19:1290-1291.
20. Paganini-Hill A. Aspirin and the prevention of colorectal cancer: a review of the evidence. Semin Surg Oncol. 1994;3:158-164.
21. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;15:1220-1224.
22. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willet WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;4:241-246.
23. Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction: a physicians' health study. Arch Intern Med. 1994;154:2649-2657.
24. Cramer JA. Identifying and improving compliance patterns: a composite plan for health care providers. In: Cramer JA, Spilker B, eds. Patient Compliance in Medical Practice and Clinical Trials. New York, NY: Raven Press; 1991:387-392.